14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ESAB vs EKSO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, ESAB Corporation (ESAB) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ESAB carries a Unified Composite Score of 27.6/100 (SELL) at $74.74 (11.9x Forward P/E, 14.8% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).
Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ESAB 27.6/100 SELL), ESAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.8% vs. -119.7% operating margin) and revenue trajectory (+13.3% vs. -38.3% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ESAB vs EKSO. Trailing 12-month operating profitability (ESAB 14.8% vs EKSO -119.7%) and valuation multiples (ESAB 11.9x vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ESAB vs EKSO Key Questions & Quantitative Answers
As of Nov 20, 2026, ESAB Corporation (ESAB) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ESAB carries a Unified Composite Score of 27.6/100 (SELL) at $74.74 (11.9x Forward P/E, 14.8% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ESAB 27.6/100 SELL), ESAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (14.8% vs. -119.7% operating margin) and revenue trajectory (+13.3% vs. -38.3% YoY).
ESAB leads the Growth & Scale pillar: ESAB posts +13.3% YoY revenue growth and -35.6% YoY earnings growth on $3.10B TTM revenue (37.6% gross margin, 14.8% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, ESAB generates $3.10B in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, ESAB deploys 22.8% of Rev ($707M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.
ESAB screens cheaper on headline valuation multiples. ESAB trades at 11.9x Forward P/E, 28.2x Trailing P/E, 0.80x PEG, and 1.6x EV/Revenue (18.6% EBITDA margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESAB (7.6% ROE) versus EKSO (-107.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ESAB carries 47.4% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.77β · 63% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.